Applied Technology

Major Step in Application of Cell Stacks

On Apr. 24, the SOFC research group of the Ningbo Institute of Material Technology, CAS built and tested the 10 units of cell stacks, with maximum power reaching 310W (H2, Air) and maximum power density reaching 0.31W/cm2 at 750℃. The maximum and minimum power of monomer cells reached 50W and 25W respectively, which means the maximum and minimum power density of monomer cells reached 0.5W/cm2 and 0.25W/cm2 respectively. This research result marked that the stability and repetitiveness of monomer cells and the cell stack level of the SOFC research group of the Ningbo Institute of Material Technology have edged into the advanced ranks.

Antofloxacin Hydrochloride——New Drug in Fluoroquinolone

Through ten years’ research, scientists at Shanghai Institute of Materia Medica (SIMM), CAS successfully developed Antofloxacin Hydrochloride, a national first class new drug in the family of fluoroquinolone with intellectual property rights (patent no. ZL97106728.7 ). In 1997, SIMM has applied for the patent of Antofloxacin Hydrochloride and its derivatives, and obtained patents of compounds, synthesis and their applications as an antibacterial drug issued by the State Intellectual Property Office in 2000. On April 15th 2009, Antofloxacin Hydrochloride was granted a New Drug License by the State Food and Drug Administration (SFDA), and will be supplied to the market soon. Since 1993, scientists at SIMM have carried out a systematic research on fluoroquinolone antibacterial drugs about their synthetic methods, structure-activity relationship, and druggability. Prof. Yang Yushe, Prof. Ji Ruyun and their colleagues adopted a new methodology in structural optimization to study the relationship on Levofloxacin in the genetic structure-drug efficacy, ?on structure-metabolic characteristics, structure-toxicity, and synthesized a series of new compounds, from which Antofloxacin Hydrochloride was identified as a fluoroquinolone antibacterial drug with new chemical structure. The inhibitory activity of Antofloxacin Hydrochloride against HERG potassium channel current IKr is 10.5 times weaker than the clinically safest Levofloxacin, 172 times weaker than Sparfloxacin, which implies that Antofloxacin Hydrochloride is more safe in its clinical applications.